New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
04:55 EDTCRME, CRME, ALR, ALR, GALE, GALE, BIND, BIND, AVNR, AVNR, OCRX, OCRX, ONVO, ONVO, OSIR, OSIR, SGNT, SGNT, SNTA, SNTA, CRIS, CRISJMP Securities to hold a conference
Healthcare Conference to be held in New York on June 24-25.
News For CRME;SNTA;SGNT;OSIR;ONVO;OCRX;AVNR;BIND;GALE;ALR;CRIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 16, 2014
15:30 EDTONVOOrganovo mentioned cautiously by White Diamond Research
Subscribe for More Information
December 15, 2014
07:10 EDTAVNRAvanir downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information
December 12, 2014
11:01 EDTAVNROptions with decreasing implied volatility
Subscribe for More Information
08:04 EDTSNTASynta Pharmaceuticals to present results from Phase 1 trial of Ganetespib
Subscribe for More Information
December 11, 2014
08:40 EDTGALEGalena presents HER2 screening data results from NeuVax Phase 3 clinical trial
Galena Biopharma announced that initial immunohistochemistry, or IHC, screening data from the NeuVax Phase 3 PRESENT, or Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment, trial was presented at the 2014 San Antonio Breast Cancer Symposium, or SABCS. The poster, entitled, "HER2 Discordant Results in Local vs. Central Testing in the Phase 3 Nelipepimut-S Trial and Implementation of Leica Bond Oracle HER2 Immunohistochemistry System for Low and Intermediate Levels of HER2 Protein Expression as a Companion Diagnostic," demonstrated that with the implementation of the Leica Bond Oracle HER2 IHC assay, preliminary limited data indicated additional patients met HER2 eligibility for PRESENT and the assay identified more precisely patients at HER2 1+ and 2+. As part of the PRESENT trial, Galena has implemented central laboratory testing for all potential patients to confirm validated and robust entry criteria, and ensure the enrollment of the targeted patient population. To improve accuracy and specificity for the HER2 1+ and 2+ status testing, and develop a companion diagnostic for NeuVax, the Leica Bond Oracle HER2 IHC system has been incorporated as central HER2 IHC screening for the PRESENT study.
08:05 EDTSNTAFDA Pediatric Oncologic Subcommittee to hold a meeting
Subscribe for More Information
December 10, 2014
15:25 EDTAVNRNotable companies reporting after market close
Subscribe for More Information
December 9, 2014
07:04 EDTALRAlere awarded CLIA waiver from FDA for HIV-1/2 Ag/Ab combo test
Subscribe for More Information
December 8, 2014
10:20 EDTAVNROptions with decreasing implied volatility
Subscribe for More Information
09:20 EDTGALEOn The Fly: Pre-market Movers
Subscribe for More Information
07:10 EDTALRAlere initiates voluntary correction for use of Alere INRatio monitor system
Subscribe for More Information
07:08 EDTGALEGalena GALE-401 Phase 1 results show reduced platelet counts, tolerable safety
Subscribe for More Information
05:50 EDTAVNRStocks with implied volatility movement; AVNR MNKD
Subscribe for More Information
December 5, 2014
10:40 EDTAVNROptions with decreasing implied volatility
Subscribe for More Information
December 4, 2014
16:35 EDTSNTASynta Pharmaceuticals appoints Chen Schor COO, Marc Schneebaum CFO
Subscribe for More Information
10:24 EDTAVNROptions with decreasing implied volatility: AVNR ASNA ANF AVGO PVH
Subscribe for More Information
10:08 EDTBINDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Anglo American (AAUKY) downgraded to Underperform from Buy at BofA/Merrill... Archer Daniels (ADM) downgraded to Hold from Buy at Miller Tabak... AuRico Gold (AUQ) downgraded to Underweight from Equal Weight at Morgan Stanley... BHP Billiton (BHP) downgraded to Neutral from Buy at BofA/Merrill... BIND Therapeutics (BIND) downgraded at Credit Suisse... BRF S.A. (BRFS) downgraded to Neutral from Buy at Goldman... CIRCOR (CIR) downgraded to Hold from Buy at BB&T... DISH (DISH) downgraded to Underweight from Equal Weight at Barclays... Enerplus (ERF) downgraded to Sector Performer from Outperformer at CIBC... Gildan Activewear (GIL) downgraded to Hold from Buy at GMP Securities... Kindred Biosciences (KIN) downgraded to Hold from Buy at Craig-Hallum... Nevsun Resources (NSU) downgraded to Neutral from Buy at UBS... Public Storage (PSA) downgraded at KeyBanc... Rio Tinto (RIO) downgraded to Underperform from Buy at BofA/Merrill... SeaChange (SEAC) downgraded to Hold from Buy at Noble Financial... Thor Industries (THO) downgraded at BMO Capital... Tupperware Brands (TUP) downgraded to Underperform from Market Perform at BMO Capital... UTi Worldwide (UTIW) downgraded at Stifel... Vale (VALE) downgraded to Neutral from Buy at BofA/Merrill... Vermilion Energy (VET) downgraded to Sector Performer from Outperformer at CIBC... Wal-Mart (WMT) downgraded to Neutral from Buy at UBS.
07:34 EDTONVOPR Newswire to hold a virtual conference
RetailInvestorConferences is being held on December 4 at 9:15 am. Webcast Link
06:29 EDTBINDBIND Therapeutics downgraded at Credit Suisse
As previously reported, Credit Suisse downgraded BIND Therapeutics to Neutral from Outperform. The firm said recent BIND-014 data does not demonstrate a visible path forward and active agents belong to an unproven drug class. Price target lowered to $10 from $20.
06:05 EDTBINDBIND Therapeutics downgraded to Neutral from Outperform at Credit Suisse
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use